Virtual Companies do they exist in Pharma????

Last week and till today I had bit hectic time in office and after our work was done was having chat with my colleague regarding the existence of virtual companies in both Pharma and biopharma domain. At this point of time what is like forming a virtual company, do we have any success stories of virtual pharma companies till date? How many existed before and after the dot com era? What are the ways these companies are able to get there venture funding?

2009 Good year for Roche :)

Roche CEO reported that they have done considerably well in year 2009, there drug Tamiflu is expected to generate more than $2.2 Billion in sales and after they acquired Genentech they have some more drugs to fill in their clinical pipeline.

For more information please click on the following link
http://in.reuters.com/article/rbssHealthcareNews/idINLDE5BJ06H20091220

Pharma Ware housing...........

Yesterday I was reading some newspaper about Next pharma going for Pharma ware housing in Germany, this concept has been existing in United States for such a long time and now this concept has taken its initial footsteps in India, I have been in touch with an architect who has been working on this type of concept for past one year in India and he told me that now Indian government is making provisions on its own side to make this pharma ware house concept a big success in the coming years :)



This week end will be updating about the series of Merger and Acquisitions happening in pharmaceutical industry.

Takeda and Pfizer New Alliance........

Today both Takeda and Pfizer Asia have announced that Takeda will promote its Diabetes pill Actos with Pfizer in republic of china, this alliance will be till 2020 and will help Takeda to access sales force 18 times than its own. This Diabetes drug Actos contributed to 26% of total revenue for Takeda i.e. ($2.2 billion) in global sales in the six months ended Sept. 30 and with access to Pfizer's 3000 strong sales force we will have double digit revenue in billion dollars for Takeda in coming financial year :).

Sanofi with Prayas for Indian Rural Market......

Sanofi Aventis India has recently initiated program called "Prayas" to capture Indian rural market, with this project at one hand Sanofi will try to sell its 15 generic products under its banner Hoechst. The drug categories to be included are anti- infection, cough & cold and pain management drugs on the other hand Prayas will also impart latest medical science updates to 100,000 general practitioners and specialists in rural areas, through regular medical workshops to be held by specialist doctors who will be hired by Sanofi. The company with this projects hopes to generate additional 50 crore INR by year 2010. For more information of this report please click on the following link

 http://www.business-standard.com/india/news/sanofi-aventis%5C-new-rural-initiative-to-push-generics/379236/

Talent Pool..........

Hi All,


I was listening to this now in Mc Kinsey Quarterly by Mr Emmanual, Principal- Heidrick and Struggles about talent hunt in China and I would appreciate if you people all also listen to this.

What I feel is at present this talent pool hunt is a major issue for all medium to big companies which are planning for huge investment in emerging markets.

Chaooooo :)

India Phama Update

India's one of the biggest generic pharmaceutical company Cipla has been charged by government agency ie,National Pharmaceutical Pricing Authority for over pricing of drug  Ciprofloxacin and Doxycyclin.NPPA has asked the company to pay Rs 20.1 crore for Ciprofloxacin and Rs 1.1 lakh for Doxycycline.

For more information about the article go to following link
http://www.business-standard.com/india/news/cipla-gets-nppa-noticeoverpricing-drugs/80176/on

Other News Update: Watson pharmaceutical has completely finished acquisition of Arrow pharma which also has generic version of Lipitor in its pipeline.
 

India Incorporation- Update I

I am back after a short hiatus, In the beginning of this week there have been lot more events happening in India and United states M&A market, India's own CIPLA is trying for a generic deal with either Pfizer or Takeda Japan , India advantage for both Pfizer and Takeda is that Pfizer's global competitor GSK has already signed deal with Dr Reddy's for 100 generic drug worldwide marketing deal and on the other had Takeda's Japanese market competitor Daichii had sometime back acquired India’s largest generic firm Ranbaxy, Now we have to wait and watch out of Uncle Sam or Japanese Samurai who is actually forming an alliance with CIPLA :)